Eighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the ...

Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst ...

The FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for ...

After the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape with ...

After committing $55 billion last year to bolster U.S. manufacturing capabilities, Johnson & Johnson is making changes to its ...

The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line ...

New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...

In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has ...

Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.

Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the ...

In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has ...

With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts ...